Tags Archive Navigation
icon
-
Media ReleaseNovartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i
-
Media ReleaseNew Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer
-
StoryWhen it comes to cancer, there’s power in a good partner
-
Media ReleaseNew data at ASH spotlight Novartis recently approved Scemblix®, next-generation CAR-T platform and expanding hematology portfolio
-
StorySolving the puzzle of immunotherapy
-
Media ReleaseFDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia
-
Featured NewsSound Up for Lung Cancer
-
StoryDemystifying the science of myelodysplastic syndromes
-
Media ReleaseNovartis top-line results for CANOPY-1 Phase III study support further evaluation of canakinumab in lung cancer
-
Media ReleasePositive survival data for Novartis investigational radioligand therapy 177Lu-PSMA-617 published in The New England Journal of Medicine
-
Media ReleaseNovartis presents important overall survival and quality-of-life results across solid tumor portfolio, among other key data at ESMO
-
Media ReleaseNovartis announces first FDA filing acceptance for anti-PD-1 antibody tislelizumab for people with esophageal cancer
Pagination
- ‹ Previous page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- …
- 15
- › Next page